An Open Label Study With an Open Dose Selection Period to Assess the Safety, Tolerability and Immunogenicity of the Drug "Gam-COVID-Vac, a Combined Vector Vaccine for the Prevention of Coronavirus Infection Caused by the SARS-CoV-2 Virus", With the Participation of Adolescent Volunteers
Latest Information Update: 04 Jan 2024
At a glance
- Drugs COVID-19 vaccine-Gamaleya National Research Center of Epidemiology and Microbiology (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms OLSTAD
- 08 Sep 2021 Planned number of patients changed from 350 to 3000.
- 08 Sep 2021 Planned primary completion date changed from 6 Oct 2022 to 6 Nov 2022.
- 13 Jul 2021 New trial record